Skip to main content
    A

    Avita Medical Ltd (RCEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.22
    -0.41 (-2.62%)

    Market Cap: $491.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Avita Medical Ltd (RCEL) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Avita Medical (RCEL) to earn $0.42 per share in the fiscal year ending Dec 31, 2026, on revenue of $134.72M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy3100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    3

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates rise 21.9%.

    Fiscal year ending Dec 31, 2026
    $0.42
    EPS consensus, revenue $134.72M
    Fiscal year ending Dec 31, 2027
    -$0.32
    EPS consensus, revenue $164.29M
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.42-$1.34 to $1.483$134.72M$132.19M to $136.44M6
    Dec 31, 2027-$0.32-$0.55 to $0.113$164.29M$154.04M to $173.05M6

    Quarterly Estimates

    The EPS consensus falls from -$0.20 for the quarter ending Dec 31, 2026 to -$0.26 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.20-$0.22 to -$0.186$26.21M$24.40M to $27.72M5
    Mar 31, 2027-$0.26-$0.31 to -$0.222$36.20M$35.21M to $38.51M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 9 upward and 3 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202642
    Fiscal year ending Dec 31, 202731
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 425.0% from $0.08.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.42$0.25$0.25$0.25$0.08+449.5%
    Fiscal year ending Dec 31, 2027-$0.32-$0.60-$0.60-$0.60-$0.61N/A
    Quarter ending Mar 31, 2027-$0.26-$0.26-$0.26-$0.26-$0.26N/A

    Frequently Asked Questions About RCEL

    What is the RCEL stock forecast?

    Consensus analyst estimates put Avita Medical's EPS at $0.42 for the fiscal year ending Dec 31, 2026, on revenue of $134.72M. The consensus rating from 3 analysts is Buy.

    How do analysts rate RCEL stock?

    Of 3 analysts covering Avita Medical, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RCEL next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.42, with estimates from -$1.34 to $1.48 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.32, with estimates from -$0.55 to $0.11 from 3 analysts.

    What revenue do analysts expect from Avita Medical next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $134.72M, with estimates from $132.19M to $136.44M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $164.29M, with estimates from $154.04M to $173.05M.

    How many analysts cover RCEL?

    3 analysts rate Avita Medical stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.